Developing a test to detect harmful antibodies related to Heparin-induced Thrombocytopenia
An in vitro diagnostic assay for the early and accurate detection of platelet-activating antibodies associated with Heparin-induced Thrombocytopenia
['FUNDING_SBIR_2'] · RETHAM TECHNOLOGIES, INC. · NIH-10653274
This study is working on a new, more accurate test to help doctors find out if patients have Heparin-induced Thrombocytopenia (HIT), a serious condition that can happen when they receive heparin treatment, so that patients can get the right care and feel better faster.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RETHAM TECHNOLOGIES, INC. (nih funded) |
| Locations | 1 site (Wauwatosa, UNITED STATES) |
| Trial ID | NIH-10653274 on ClinicalTrials.gov |
What this research studies
This research focuses on creating a highly accurate diagnostic test to identify pathogenic antibodies associated with Heparin-induced Thrombocytopenia (HIT), a serious condition that can occur in patients receiving heparin treatment. The approach utilizes Platelet Factor 4 (PF4)-treated platelets to enhance the sensitivity and specificity of the test, addressing the limitations of existing assays. By improving the accuracy of HIT diagnosis, this research aims to reduce the number of patients who are misdiagnosed and inappropriately treated, ultimately leading to better patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients who are receiving heparin treatment and are suspected of having Heparin-induced Thrombocytopenia.
Not a fit: Patients who are not receiving heparin or those who do not have a risk of developing Heparin-induced Thrombocytopenia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the diagnosis of Heparin-induced Thrombocytopenia, leading to more appropriate treatment and better patient safety.
How similar studies have performed: Previous research has shown that improving diagnostic assays for HIT can lead to better patient management, indicating that this approach has the potential for success.
Where this research is happening
Wauwatosa, UNITED STATES
- RETHAM TECHNOLOGIES, INC. — Wauwatosa, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JONES, CURTIS — RETHAM TECHNOLOGIES, INC.
- Study coordinator: JONES, CURTIS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.